RBC Capital on Biogen (BIIB): 'FDA Summary Review Now Available; We Believe Suggests High Amenability For Future Full Leca Approval'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $362.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "FDA's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
